# Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy

> **NCT05111197** · PHASE3 · UNKNOWN · sponsor: **Institut Cancerologie de l'Ouest** · enrollment: 112 (estimated)

## Conditions studied

- Locally Advanced Non Small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer

## Interventions

- **RADIATION:** SRT
- **DRUG:** Immunotherapy

## Key facts

- **NCT ID:** NCT05111197
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-12
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05111197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05111197, "Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05111197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*